SCHEMBL23246010

SCHEMBL23246010

Nc1ccc(N2CCN(CCN3CCOCC3)CC2)nc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.44
HPGD P15428 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
HSD17B10 Q99714 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
HTT P42858 1/20 0.44
RECQL P46063 1/20 0.44
KMT2A Q03164 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
GRIN2D O15399 1/20 0.44
GRIN3B O60391 1/20 0.44
GRIN1 Q05586 1/20 0.44
GRIN2A Q12879 1/20 0.44
GRIN2B Q13224 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29618438 1.00 ALDH1A1 (0.44) ALDH1A1HPGDSMN1; SMN2HSD17B10CYP1A2
SCHEMBL29536679 0.87 ALDH1A1 (0.55) ALDH1A1HPGDSMN1; SMN2HSD17B10CYP1A2
SCHEMBL48764 0.87 ALDH1A1 (0.55) ALDH1A1HPGDSMN1; SMN2HSD17B10CYP1A2
SCHEMBL3398170 0.83 GAA (0.55) CYP2C9MEN1GAAKMT2AGRIN2D
SCHEMBL19998348 0.82 GRIN2D (0.59) ALDH1A1HPGDSMN1; SMN2HSD17B10CYP1A2
SCHEMBL29499599 0.82 GRIN2D (0.59) ALDH1A1HPGDSMN1; SMN2HSD17B10CYP1A2
SCHEMBL2744078 0.81 CNR2 (0.53) ALDH1A1HPGDSMN1; SMN2HSD17B10CYP1A2
SCHEMBL1682870 0.80 GAA (0.57) SMN1; SMN2KDM4EGAAMAPTGRIN2D
SCHEMBL1725429 0.79 MAP4K4 (0.57) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL3398177 0.79 TLR7 (0.46) GAAGRIN2DGRIN3BGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4045506-B1 DERIVATIVES OF 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-N-(PYRIDIN-3-YL) PYRIMIDIN-2- AMINE FOR TREATING PROLIFERATIVE DISEASES AND CONDITIONS AUCENTRA THERAPEUTICS PTY LTD (AU) 2025-07-23 EP disclosed
CN-114502555-B Derivatives of 4- (imidazo [1,2-a ] pyridin-3-yl) -N- (pyridin-3-yl) pyrimidin-2-amine for the treatment of proliferative diseases and disorders 常州千红生化制药股份有限公司 2024-07-16 CN disclosed
US-20240158391-A1 DERIVATIVES OF 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-N-(PYRIDIN-3-YL) PYRIMIDIN-2- AMINE FOR TREATING PROLIFERATIVE DISEASES AND CONDITIONS AUCENTRA THERAPEUTICS PTY LTD (AU) 2024-05-16 US disclosed
CN-114502555-A Derivatives of 4- (imidazo [1,2-a ] pyridin-3-yl) -N- (pyridin-3-yl) pyrimidin-2-amines for the treatment of proliferative diseases and disorders 常州千红生化制药股份有限公司 2022-05-13 CN disclosed
WO-2021072475-A1 DERIVATIVES OF 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-N-(PYRIDIN-3-YL) PYRIMIDIN-2- AMINE FOR TREATING PROLIFERATIVE DISEASES AND CONDITIONS AUCENTRA THERAPEUTICS PTY LTD (AU) 2021-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158391-A1 DERIVATIVES OF 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-N-(PYRIDIN-3-YL) PYRIMIDIN-2- AMINE FOR TREATING PROLIFERATIVE DISEASES AND CONDITIONS CDK9, CDK4, CDK2 ALDH1A1 2799/4885HPGD 2155/4885SMN1; SMN2 2551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.